A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 414 participants.

Also called NCT06037252

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 414 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06037252
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Mexico, Türkiye (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06037252. Randomized; double masking; primary purpose treatment. Start 2023-09-21 (actual); primary completion 2026-01-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Condition
Obesity
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06037252
Content hash
e6674c285e0a81081343560d62859b25a52beb8589df3dae0e25fd6fc04c8c38